Considering that IDO2 and TDO are poorly known in the field of cancer, future studies should also consider whether blocking TDO and/or IDO2 could provide general efficacy and reduce the inherent or acquired resistance to IDO1 blockade. The gene discussed is IDO2; the disease is cancer.